English

Lantern Pharma Inc.

EDGAR

LTRN Quarterly report (10-Q) · filed 2026-08-14

34 filing records in this dataset, filed from 2020-04-16 to 2026-08-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 6.66 million USD 2026-06-30 Source
Exact value

6660170 USD
Long-term debt including current maturities: Not available
Shares outstanding: 12.8 million shares 2026-06-30 Source
Exact value

12759146 shares

Reported share-count change

18.31% · 1.97 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

10784725 shares · 2025-06-30· Source
12759146 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-18.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -4177423 USD · 2025-07-01 – 2025-09-30 Source
Net income: -17119000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -13045000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -3329171 USD · 2026-01-01 – 2026-03-31 Source
Net income: -7072124 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-14.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -12884867 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -8312887 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -15676980 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -12884867 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -3772627 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -6713540 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -3772627 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

1.72 thousand USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Capital expenditure: 1159 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 1159 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 1159 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 1714 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1159 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 1715 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 1714 USD · 2025-01-01 – 2025-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-14.

Financial data available through: 2025-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 5 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 5 of 11 periods available· newest 2025-12-31
Total assets: 7 of 11 periods available· newest 2025-12-31
Total liabilities: 7 of 11 periods available· newest 2025-12-31
Current assets: 7 of 11 periods available· newest 2025-12-31
Current liabilities: 7 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 3.66 million

Prior period

−USD 20.78 million

2024-01-01 – 2024-12-31
Current period

−USD 17.12 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-17119000 − -20781000 = 3662000 USD

-20781000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-17119000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Lantern Pharma Inc. · 2025-12-31 Lantern Pharma Inc. (edgar:1763950) Year-over-year change in Net income: 3662000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -17119000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1798939 Filing: 000149315226013612 Input fundies:NetIncome: -20781000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1799248 Filing: 000149315226013612
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 2.14 million

Prior period

−USD 17.81 million

2024-01-01 – 2024-12-31
Current period

−USD 15.68 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-15676980 − -17813201 = 2136221 USD

-17813201 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-15676980 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Lantern Pharma Inc. · 2025-12-31 Lantern Pharma Inc. (edgar:1763950) Year-over-year change in Operating cash flow: 2136221 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -15676980 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1762471 Filing: 000149315226013612 Input fundies:OperatingCashFlow: -17813201 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1762935 Filing: 000149315226013612
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-86.4%

Prior period

USD 12,595

2024-01-01 – 2024-12-31
Current period

USD 1,715

2025-01-01 – 2025-12-31

Exact inputs and evidence

1715 − 12595 = -10880 USD

12595 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1715 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Lantern Pharma Inc. · 2025-12-31 Lantern Pharma Inc. (edgar:1763950) Year-over-year change in Capital expenditure: -10880 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1715 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1764445 Filing: 000149315226013612 Input fundies:CapitalExpenditure: 12595 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1764782 Filing: 000149315226013612
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 2.43 million Exact value Exact value: -2428185 USD 2019-01-01 – 2019-12-31: -2428185 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lantern Pharma Inc. · 2019-12-31 Lantern Pharma Inc. (edgar:1763950) Net Income: -2428185 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2428185 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000121390021014576/ltrn-20201231.xml#51477 Filing: 000121390021014576 The citation records this snapshot. The page link may show a newer release later.	−USD 2.13 million Exact value Exact value: -2127923 USD 2019-01-01 – 2019-12-31: -2127923 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lantern Pharma Inc. · 2019-12-31 Lantern Pharma Inc. (edgar:1763950) Operating Cash Flow: -2127923 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2127923 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000121390021014576/ltrn-20201231.xml#66665 Filing: 000121390021014576 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 5.91 million Exact value Exact value: -5908190 USD 2020-01-01 – 2020-12-31: -5908190 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lantern Pharma Inc. · 2020-12-31 Lantern Pharma Inc. (edgar:1763950) Net Income: -5908190 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5908190 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000121390022011581/f10k2021_lanternpharma.htm#1151221 Filing: 000121390022011581 The citation records this snapshot. The page link may show a newer release later.	−USD 5.65 million Exact value Exact value: -5651621 USD 2020-01-01 – 2020-12-31: -5651621 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lantern Pharma Inc. · 2020-12-31 Lantern Pharma Inc. (edgar:1763950) Operating Cash Flow: -5651621 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5651621 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000121390022011581/f10k2021_lanternpharma.htm#1238029 Filing: 000121390022011581 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 12.36 million Exact value Exact value: -12363000 USD 2021-01-01 – 2021-12-31: -12363000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lantern Pharma Inc. · 2021-12-31 Lantern Pharma Inc. (edgar:1763950) Net Income: -12363000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12363000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315223008241/form10-k.htm#1669081 Filing: 000149315223008241 The citation records this snapshot. The page link may show a newer release later.	−USD 10.59 million Exact value Exact value: -10591543 USD 2021-01-01 – 2021-12-31: -10591543 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lantern Pharma Inc. · 2021-12-31 Lantern Pharma Inc. (edgar:1763950) Operating Cash Flow: -10591543 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10591543 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315223008241/form10-k.htm#1628657 Filing: 000149315223008241 The citation records this snapshot. The page link may show a newer release later.	USD 15,499 Exact value Exact value: 15499 USD 2021-01-01 – 2021-12-31: 15499 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lantern Pharma Inc. · 2021-12-31 Lantern Pharma Inc. (edgar:1763950) Capital Expenditure: 15499 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15499 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315223008241/form10-k.htm#1630482 Filing: 000149315223008241 The citation records this snapshot. The page link may show a newer release later.	−USD 10.61 million Calculation and evidence -10591543 − 15499 USD Exact free cash flow: -10607042 USD 2021-01-01 – 2021-12-31: -10591543 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 15499 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lantern Pharma Inc. · 2021-12-31 Lantern Pharma Inc. (edgar:1763950) Free cash flow: -10607042 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10591543 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315223008241/form10-k.htm#1628657 Filing: 000149315223008241 Input fundies:CapitalExpenditure: 15499 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315223008241/form10-k.htm#1630482 Filing: 000149315223008241 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 14.26 million Exact value Exact value: -14260000 USD 2022-01-01 – 2022-12-31: -14260000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lantern Pharma Inc. · 2022-12-31 Lantern Pharma Inc. (edgar:1763950) Net Income: -14260000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14260000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315224010302/form10-k.htm#1663724 Filing: 000149315224010302 The citation records this snapshot. The page link may show a newer release later.	−USD 12.77 million Exact value Exact value: -12767492 USD 2022-01-01 – 2022-12-31: -12767492 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lantern Pharma Inc. · 2022-12-31 Lantern Pharma Inc. (edgar:1763950) Operating Cash Flow: -12767492 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12767492 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315224010302/form10-k.htm#1625348 Filing: 000149315224010302 The citation records this snapshot. The page link may show a newer release later.	USD 27,844 Exact value Exact value: 27844 USD 2022-01-01 – 2022-12-31: 27844 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lantern Pharma Inc. · 2022-12-31 Lantern Pharma Inc. (edgar:1763950) Capital Expenditure: 27844 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 27844 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315224010302/form10-k.htm#1627209 Filing: 000149315224010302 The citation records this snapshot. The page link may show a newer release later.	−USD 12.8 million Calculation and evidence -12767492 − 27844 USD Exact free cash flow: -12795336 USD 2022-01-01 – 2022-12-31: -12767492 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 27844 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lantern Pharma Inc. · 2022-12-31 Lantern Pharma Inc. (edgar:1763950) Free cash flow: -12795336 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12767492 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315224010302/form10-k.htm#1625348 Filing: 000149315224010302 Input fundies:CapitalExpenditure: 27844 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315224010302/form10-k.htm#1627209 Filing: 000149315224010302 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 15.96 million Exact value Exact value: -15962000 USD 2023-01-01 – 2023-12-31: -15962000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lantern Pharma Inc. · 2023-12-31 Lantern Pharma Inc. (edgar:1763950) Net Income: -15962000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15962000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000164117225000926/form10-k.htm#1788828 Filing: 000164117225000926 The citation records this snapshot. The page link may show a newer release later.	−USD 14.35 million Exact value Exact value: -14346548 USD 2023-01-01 – 2023-12-31: -14346548 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lantern Pharma Inc. · 2023-12-31 Lantern Pharma Inc. (edgar:1763950) Operating Cash Flow: -14346548 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14346548 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000164117225000926/form10-k.htm#1754524 Filing: 000164117225000926 The citation records this snapshot. The page link may show a newer release later.	USD 18,734 Exact value Exact value: 18734 USD 2023-01-01 – 2023-12-31: 18734 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lantern Pharma Inc. · 2023-12-31 Lantern Pharma Inc. (edgar:1763950) Capital Expenditure: 18734 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18734 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000164117225000926/form10-k.htm#1756368 Filing: 000164117225000926 The citation records this snapshot. The page link may show a newer release later.	−USD 14.37 million Calculation and evidence -14346548 − 18734 USD Exact free cash flow: -14365282 USD 2023-01-01 – 2023-12-31: -14346548 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 18734 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lantern Pharma Inc. · 2023-12-31 Lantern Pharma Inc. (edgar:1763950) Free cash flow: -14365282 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14346548 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000164117225000926/form10-k.htm#1754524 Filing: 000164117225000926 Input fundies:CapitalExpenditure: 18734 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000164117225000926/form10-k.htm#1756368 Filing: 000164117225000926 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 20.78 million Exact value Exact value: -20781000 USD 2024-01-01 – 2024-12-31: -20781000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lantern Pharma Inc. · 2024-12-31 Lantern Pharma Inc. (edgar:1763950) Net Income: -20781000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20781000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1799248 Filing: 000149315226013612 The citation records this snapshot. The page link may show a newer release later.	−USD 17.81 million Exact value Exact value: -17813201 USD 2024-01-01 – 2024-12-31: -17813201 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lantern Pharma Inc. · 2024-12-31 Lantern Pharma Inc. (edgar:1763950) Operating Cash Flow: -17813201 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17813201 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1762935 Filing: 000149315226013612 The citation records this snapshot. The page link may show a newer release later.	USD 12,595 Exact value Exact value: 12595 USD 2024-01-01 – 2024-12-31: 12595 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lantern Pharma Inc. · 2024-12-31 Lantern Pharma Inc. (edgar:1763950) Capital Expenditure: 12595 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12595 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1764782 Filing: 000149315226013612 The citation records this snapshot. The page link may show a newer release later.	−USD 17.83 million Calculation and evidence -17813201 − 12595 USD Exact free cash flow: -17825796 USD 2024-01-01 – 2024-12-31: -17813201 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 12595 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lantern Pharma Inc. · 2024-12-31 Lantern Pharma Inc. (edgar:1763950) Free cash flow: -17825796 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17813201 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1762935 Filing: 000149315226013612 Input fundies:CapitalExpenditure: 12595 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1764782 Filing: 000149315226013612 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 17.12 million Exact value Exact value: -17119000 USD 2025-01-01 – 2025-12-31: -17119000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lantern Pharma Inc. · 2025-12-31 Lantern Pharma Inc. (edgar:1763950) Net Income: -17119000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17119000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1798939 Filing: 000149315226013612 The citation records this snapshot. The page link may show a newer release later.	−USD 15.68 million Exact value Exact value: -15676980 USD 2025-01-01 – 2025-12-31: -15676980 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lantern Pharma Inc. · 2025-12-31 Lantern Pharma Inc. (edgar:1763950) Operating Cash Flow: -15676980 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15676980 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1762471 Filing: 000149315226013612 The citation records this snapshot. The page link may show a newer release later.	USD 1,715 Exact value Exact value: 1715 USD 2025-01-01 – 2025-12-31: 1715 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lantern Pharma Inc. · 2025-12-31 Lantern Pharma Inc. (edgar:1763950) Capital Expenditure: 1715 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1715 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1764445 Filing: 000149315226013612 The citation records this snapshot. The page link may show a newer release later.	−USD 15.68 million Calculation and evidence -15676980 − 1715 USD Exact free cash flow: -15678695 USD 2025-01-01 – 2025-12-31: -15676980 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 1715 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lantern Pharma Inc. · 2025-12-31 Lantern Pharma Inc. (edgar:1763950) Free cash flow: -15678695 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:12:59Z Snapshot: 273a7dc3db38f71800675d45053313b0b18f5a3504130d5a6e84254a7d371558 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1763950?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15676980 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1762471 Filing: 000149315226013612 Input fundies:CapitalExpenditure: 1715 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1763950/000149315226013612/form10-k.htm#1764445 Filing: 000149315226013612 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

34 filings · 1,326 latest values · 1,326 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001763950, 1763950, LTRN, edgar:1763950

Also known as Lantern Pharma, Lantern Pharma Inc.

Lantern Pharma Inc.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation